ArticleParasites & vectors2026
Can dual active ingredient Interceptor® G2 insecticide-treated net (ITN) replace indoor residual spraying (IRS) efficiently? A case study in Sakassou, Côte d'Ivoire.
Article in Parasites & vectors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFollowing three successful rounds of indoor residual spraying (IRS) implementation in the district of Sakassou (Côte d'Ivoire), IRS was withdrawn and replaced by insecticide-treated nets (ITNs). This study evaluated the entomological and epidemiological impacts of Interceptor (IG2) ITNs distributed in Sakassou to determine whether the protection offered by IG2 ITNs was adequate to suppress malaria transmission post-IRS withdrawal.
methodsThis study is a quasi-experimental evaluation using historical data and additional data collections on entomological indicators and malaria incidence to assess malaria transmission trends in Sakassou. The vector control optimization model was adapted to evaluate the effectiveness of the IRS and IG2 ITN deployment on malaria transmission dynamics. Additionally, we used an interrupted time series model to analyze routinely reported malaria cases in the District Health Information Management System (DHIS2) to determine the epidemiological impact of both interventions. Counterfactual trends were generated for the post-IRS withdrawal period during which IG2 ITNs were distributed.
resultsThe results showed a 55.4% (95% CI 48.3-62.4%) reduction in the human biting rate (HBR) when IRS was deployed and 48.8% (95% CI 42.8-54.6%) when IG2 ITNs were distributed, compared with standard pyrethroid-only nets. No statistical difference was recorded between the HBR of IG2 ITNs and IRS (P = 0.164) during the implementation of IG2 ITNs and the counterfactual of IRS. Similarly, IRS resulted in a 64.7% (95% CI 56.6-72.8%) decline in EIR while IG2 ITNs resulted in a comparable reduction of 61.9% (95% CI 54.2-69.6% ;P = 0.616) over the same period. Furthermore, a 26% reduction in malaria cases was recorded immediately after spraying (IRR = 1.02; 95% CI 1.00-1.04; P = 0.005) with cumulative impact over time and spray rounds and was similar to IG2 performance (IRR = 1.03; CI 1.00-1.07; P = 0.040).
conclusionsThe study findings suggest that IG2 ITNs provided entomological efficacy comparable to clothianidin-based IRS but could not adequately suppress malaria cases after IRS withdrawal, possibly due to plastic-vector feeding behavior and late timing of IG2 deployment. Overall, the study shows how the dynamics of malaria transmission and operational decisions could impact the effectiveness of both IRS and ITNs as vector control tools. These findings provide key information for malaria programs and policymakers to consider when deploying vector control interventions as countries work toward malaria elimination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.